Table 2 Summary of clinical results reported in the main adjuvant trials with new drugs
From: New paradigm for stage III melanoma: from surgery to adjuvant treatment
Author | Study | Recruitment years | No. patients | Inclusion | Treatment | HR for PFS | 95% CI | 2-year PFS | 3-year PFS | 4-year PFS | 5-year PFS |
|---|---|---|---|---|---|---|---|---|---|---|---|
Eggermont et al. [16] | EORTC 18071 | 2008–2011 | 951 | III (> 1 mm) | Ipilimumab vs placebo | 0.75 | 0.64–0.90 | 46.5% | 40.8% | ||
Weber et al. [5] | CheckMate238 | Mar–Nov 2015 | 906 | IIIB-IIIC/IV | Nivolumab vs ipilimumab | 0.65 | 0.51–0.83 | 63% | – | – | – |
Long et al. [6] | COMBI-AD | 2013–2014 | 870 | III (> 1 mm) | Dabrabenif/trametinib vs placebo | 0.49 | 0.40–0.59 | 67% | 59% | 54% | |
Maio et al. [14] | BRIM8 | 2012–2015 | 498 | IIC, IIIA, IIIB IIIC | Vemurafenib vs placebo | 0.54 0.80 | 0.37–0.78 0.54–1.18 | 72.3% 46.3% | |||
Eggermont et al. [7] | KeyNote 054 | 2015–2016 | 1019 | III (> 1 mm) | Pembrolizumab vs placebo | 0.57 | 0.43–0.74 | 71.4% (18 months) | – | – | – |